z-logo
open-access-imgOpen Access
Evaluation of sensitivity and spesitivity as COVID–19 screening method
Author(s) -
Atikah Nurhesti,
Solikhah Solikhah,
Siti Nur Djannah
Publication year - 2021
Publication title -
international journal of public health science
Language(s) - English
Resource type - Journals
eISSN - 2620-4126
pISSN - 2252-8806
DOI - 10.11591/ijphs.v10i4.20919
Subject(s) - covid-19 , gold standard (test) , medicine , predictive value , antibody , predictive value of tests , gastroenterology , immunology , disease , infectious disease (medical specialty)
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Antibody rapid test is one of the COVID-19 screening tests that can be used in the community. The accuracy of the rapid antibody methods needs to be appropriately assessed, it is necessary to carry out a diagnostic accuracy study using a pairwise sensitivity and specificity analysis. This research aimed to assess the sensitivity and specificity of COVID-19 rapid tests, also assesses positive predictive value (PPV) and negative predictive value (NPV) of the rapid antibody test as a method of screening for COVID-19 in Sleman Regency, Indonesia. In total, 118 respondents who have contact with COVID-19 patients and have symptoms were enrolled in this study. The study was conducted on 118 patients who had been in contact with confirmed COVID-19 118 patients who met the close contact criteria were conducted a rapid antibody test. 64.41% patients were reactive. Real-time polymerase chain reaction (RT PCR) as a gold standard was also carried out for all patients and 63.56% affirmed positive for COVID-19. The sensitivity value was 97.33%, and the specificity value was 93.02%, while the positive predictive value (NPP) was 96.05%, and the negative predictive value (NPN) was 95.24%. These results meet the minimum recommendations for the screening method.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here